


Anti-Human CD267 (TACI) PE

Catalog Number: 12-9217

Also Known As: TNFRSF13B

RUO: For Research Use Only. Not for use in diagnostic procedures.



Staining of normal human peripheral blood cells with Anti-Human CD19 FITC (cat. 11-0199) and Mouse IgG2a kappa Isotype Control PE (cat. 12-4724) (left) or Anti-Human CD267 (TACI) PE (right). Cells in the lymphocyte gate were used for analysis.

Product Information

Contents: Anti-Human CD267 (TACI) PE

REF **Catalog Number:** 12-9217

Clone: 11H3

Concentration: 5 μ L (0.25 μ g)/test

Host/Isotype: Mouse IgG2a

Formulation: aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer



Temperature Limitation: Store at 2-8°C. Do not freeze. Light sensitive material.



Batch Code: Refer to Vial



Use By: Refer to Vial



Caution, contains Azide

Description

The 11H3 antibody reacts with human TACI, also known as tumor necrosis factor receptor 13B. TACI, like BCMA, binds BAFF and APRIL. TACI and its ligands regulate humoral immune responses, activate NF- κ B and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases. TACI mRNA and protein are found predominantly in B-cells and correlate with BLyS binding in a panel of B-cell lines. TACI interacts with nanomolar affinity with the BLyS-related tumor necrosis factor homologue APRIL for which no clear *in vivo* role has been described. 11H3 does not block binding of BAFF/BLyS to TACI.

Applications Reported

This 11H3 antibody has been reported for use in flow cytometric analysis.

Applications Tested

This 11H3 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μ L (0.25 μ g) per test. A test is defined as the amount (μ g) of antibody that will stain a cell sample in a final volume of 100 μ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

References

von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. *Immunity*. 2001 May;14(5):573-82.

Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kallied SL, Mackay F, Mackay CR. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. *J Immunol*. 2004 Jul 15;173(2):807-17.

Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. *Blood*. 2004 Jan 15;103(2):689-94.

Sakurai D, Kanno Y, Hase H, Kojima H, Okumura K, Kobata T. TACI attenuates antibody production costimulated by BAFF-R and CD40. *Eur J Immunol*. 2007 Jan;37(1):110-8. PubMed

Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. *Blood*. 2007 Apr 1;109(7):2961-7. PubMed

Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity,

establishing TACI as an inhibitory BLyS receptor. *Immunity*. 2003 Feb;18(2):279-88.

Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM. Activation and accumulation of B cells in TACI-deficient mice. *Nat Immunol*. 2001 Jul;2(7):638-43.

Related Products

11-0199 Anti-Human CD19 FITC (HIB19)

12-4724 Mouse IgG2a K Isotype Control PE

Not for further distribution without written consent.

Copyright © 2000-2010 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com